Cover Image

OP 5.3 - 00082 1-year treatment with ponatinib provides protection of CD4+T cells against HIV that is maintained at least 1 year more after treatment interruption

Saved in:

Bibliographic Details
Main Authors:	M. Manzanares (Author), F. Ramos-Martín (Author), G. Casado-Fernández (Author), M. Torres (Author), E. Mateos (Author), L. Vigón (Author), S. Rodríguez-Mora (Author), V. García-Gutiérrez (Author), V. Planelles (Author), M. Coiras (Author)
Format:	Book
Published:	Elsevier, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Sustained antiviral response against in vitro HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib
by: Mario Manzanares, et al.
Published: (2024)

OP 5.5 - 00083 Impairment of HIV proviral reactivation by interfering with essential metabolic pathways in effector memory CD4+ T cells
by: G. Casado Fernández, et al.
Published: (2022)

CD4 T cells from patients with chronic myeloid leukemia are resistant to HIV-1 proviral integration and transcription after prolonged withdrawal of treatment with tyrosine kinase inhibitors
by: Lorena Vigón, et al.
Published: (2019)

Ponatinib induced pityriasis rubra pilaris: Case report and review of literature
by: Sejal Jain, et al.
Published: (2023)

Ponatinib: A Review of the History of Medicinal Chemistry behind Its Development
by: Mayara Nascimento, et al.
Published: (2024)

Analytical treatment interruption and rearrangement of HIV-1 drug resistance mutations in peripheral reservoir
by: E. Bruzzesi, et al.
Published: (2019)

OP 7.3 - 00139 Pre-treatment Interruption Plasma Metabolites and Glycans Correlate with Time to HIV Rebound and Reservoir Size in ACTG A5345
by: L.B. Giron, et al.
Published: (2022)

Ponatinib modulates the metabolic profile of obese mice by inhibiting adipose tissue macrophage inflammation
by: Zhuomiao Lin, et al.
Published: (2022)

13 HIV-1-specific ADCC following anti-latency therapy and analytical treatment interruption
by: W.S. Lee, et al.
Published: (2017)

Drug-Induced Reorganisation of Lipid Metabolism Limits the Therapeutic Efficacy of Ponatinib in Glioma Stem Cells
by: Paula Aldaz, et al.
Published: (2024)

Ponatinib Induces a Procoagulant Phenotype in Human Coronary Endothelial Cells via Inducing Apoptosis
by: Bálint Krajcsir, et al.
Published: (2024)

OP 1.1 Sequencing HIV: Significance and Impact
by: S. Palmer
Published: (2022)

OP 8.4 - 00165 TLR agonist and SIV mAbs administered to SIV-infected ART-suppressed macaques did not delay rebound after treatment interruption
by: H. King, et al.
Published: (2022)

OP 2.6 - 00135 Constitutive NKG2A levels and timing of antiretroviral therapy initiation impact the potential role of NK cells after treatment interruption - the pVISCONTI study
by: A. Chapel, et al.
Published: (2022)

Sociodemographic inequities in cervical cancer screening, treatment and care amongst women aged at least 25 years: evidence from surveys in Harare, Zimbabwe
by: O. Tapera, et al.
Published: (2019)

OP 2.1 CCR5 in HIV Prevention and Cure
by: Helen L. Wu, et al.
Published: (2022)

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
by: Jonathan I. Silverberg, et al.
Published: (2024)

OP 4.1 Viral persistence and NK cells
by: Michaela Müller-Trutwin
Published: (2022)

OP 3.1 HIV Persistence in women, an update
by: N. Archin
Published: (2022)

Cervical cancer knowledge, attitudes, beliefs and practices of women aged at least 25 years in Harare, Zimbabwe
by: O. Tapera, et al.
Published: (2019)

Prevention and Treatment of Iron-deficiency Anemia in Children under 1 Year of Age
by: A. G. Rumyantsev, et al.
Published: (2015)

Retrospective cohort study of rough-surface titanium implants with at least 25 years' function
by: Tadashi Horikawa, et al.
Published: (2017)

Root coverage stability: A systematic overview of controlled clinical trials with at least 5 years of follow‐up
by: Kristina Bertl, et al.
Published: (2021)

OP 1.6 - 00138 Role of UHRF1 in HIV-1 transcriptional repression through epigenetic and non-epigenetic mechanisms
by: A. Aït-Ammar, et al.
Published: (2022)

Immediate implant placement following tooth extraction with simultaneous lateral sinus augmentation: a retrospective clinical study after at least 1 year of loading
by: Bok-Joo Kim, et al.
Published: (2021)

Continuing breastfeeding for at least two years after birth in rural Vietnam: prevalence and psychosocial characteristics
by: Hemavarni Doma, et al.
Published: (2021)

Diverse interferons restrict HIV-1 Infection in macrophages through activation of SAMHD1
by: M. Szaniawski, et al.
Published: (2017)

Publisher Correction: Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
by: Jonathan I. Silverberg, et al.
Published: (2024)

Peripheral blood lymphocytes from patients with chronic myeloid leukemia on treatment with dasatinib are resistant to HIV-1 infection
by: M. Coiras, et al.
Published: (2015)

OP 1.3 - 00017 The fraction of cells with unspliced HIV RNA is not associated with plasma viremia
by: A. Capoferri, et al.
Published: (2022)

OP 7.2 - 00035 Impact of 10-1074LS and 3BNC117-LS on viral rebound dynamics following treatment interruption six months after dosing: four cases from the open label arm of the RIO trial
by: M. Lee, et al.
Published: (2022)

Op maat van het midden- en kleinbedrijf: deel 1
by: WRR
Published: (1987)

Delta-Like-1 Changes the Immunomodulatory Property of OP9 Cells
by: Lei Zhang, et al.
Published: (2016)

Er:YAG pre-treatment for bonding of orthodontic bracket: 1 year of in vitro treatment
by: de Jesus Tavarez RR, et al.
Published: (2017)

Most Systematic Reviews and Meta-analyses Reporting Clinical Outcomes of the Remplissage Procedure Have at Least 1 Form of Spin
by: Tom R. Doyle, M.B., M.Ch, et al.
Published: (2024)

Using barcoded HIV-1 to understand inducibility of the latent HIV-1 reservoir
by: E. Larragoite, et al.
Published: (2017)

EVALUATION OF METABOLIC BIOCHEMICAL TESTS, BODY MASS INDEX VALUES AND PERIODONTAL / PERI-IMPLANT CLINICAL PARAMETERS OF PATIENTS REHABILITATED WITH PROSTHETIC DENTAL IMPLANTS OF AT LEAST 1 YEAR
by: Mihaela Cornelia Doru (Butnaru), et al.
Published: (2023)

14 Treatment with tyrosine kinase inhibitors make PBMCs from patients with chronic myeloid leukemia less susceptible to HIV-1 infection: control of CD4+ T cell activation to control HIV-1 replication
by: Mercedes Bermejo, et al.
Published: (2017)

A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
by: Eugène D.M.B. Kroon, et al.
Published: (2020)

The innovative bridge in PH positivity- efficacy and side effect profile of inotuzomab ozogamicin and ponatinib combination in relapsed PH positive and PH like all
by: Vijayshree Muthu kumar, et al.
Published: (2024)